EBS Emergent BioSolutions Inc.

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

-  Organizations Join Together to Raise Awareness of Overdose Reversal Medicines During August 31st Games

GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentially lifesaving overdose reversal medicines on International Overdose Awareness Day 2020. International Overdose Awareness Day is a global event held on August 31 each year that aims to raise awareness of overdose and reduce the stigma of drug-related deaths. Emergent, in collaboration with these teams and MAPDA, will address the importance of accessing overdose reversal medicines through special announcements, videos, and stadium presentations.

“Emergent is committed to doing everything we can to increase awareness, access, and availability of potentially lifesaving overdose reversal medicines,” said Doug White, SVP and devices business unit head at Emergent BioSolutions. “We are proud to team up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA on International Overdose Awareness Day to highlight the important role that overdose reversal medicines play in preparing individuals and families in the event of an accidental opioid overdose. Everyone can take a stand and take action by talking to their doctor or pharmacists about having immediate access to overdose reversal medicines.”

“By increasing awareness about the importance of having immediate access to overdose reversal medicines, we may empower individuals to be prepared in the event of an opioid overdose emergency,” said Mary Bono, former U.S. Congresswoman and chairman and CEO of MAPDA. “MAPDA is honored to stand alongside Emergent, the Boston Red Sox, Cincinnati Reds, and Philadelphia Phillies, to help more individuals know about and access potentially lifesaving medicines to treat opioid overdoses.”

For more information, visit: .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.

About MAPDA

Mothers Against Prescription Drug Abuse (MAPDA) is a nonprofit consumer organization started by three mothers who lost children to prescription drug overdoses. The organization aims to prevent prescription drug abuse before it starts and support individuals in recovery. Mary Bono, a well-known political speaker and consumer advocate, now heads up the organization headquartered in the Washington DC suburbs. Learn more at MAPDA.net.

Media Contact:

Miko B. Neri

Senior Director, Global Communications & Public Affairs

240-631-3392

 

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

  

EN
31/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manu...

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax. “We are pleased with the U.S. FDA approval of our sBLA f...

 PRESS RELEASE

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approv...

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose. This historic approval made the life-saving medication easy to administer in both medical and community settings, ultimately l...

 PRESS RELEASE

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan fr...

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its shareholders. “For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent’s mission to protect and save lives,” said Joe Papa, president and CEO of Emergent. “On behalf of the Board and the entire Emergent team, I want to...

 PRESS RELEASE

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Reports Third Quarter 2025 Financial Results Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven b...

 PRESS RELEASE

Emergent BioSolutions Releases New Survey Findings Revealing Heightene...

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch